News | June 28, 2025
Shukra Pharmaceuticals receives LoA from RMSCL
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Star Health Insurance is modernising its claims ecosystem to be future-ready
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Changhua site meets international regulatory standards for global medical applications
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The transaction is expected to close in Q2 FY 2026
Subscribe To Our Newsletter & Stay Updated
